Valbenazine

Phase 2Completed
0 watching 0 views this week Active
49
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tourette Syndrome

Conditions

Tourette Syndrome

Trial Timeline

Feb 8, 2018 → Jul 12, 2019

About Valbenazine

Valbenazine is a phase 2 stage product being developed by Neurocrine Biosciences for Tourette Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03444038. Target conditions include Tourette Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (8)

NCT IDPhaseStatus
NCT07105111ApprovedRecruiting
NCT05053321Phase 1Withdrawn
NCT06312189Phase 3Recruiting
NCT05859698ApprovedCompleted
NCT04400331Phase 3Active
NCT03444038Phase 2Completed
NCT02879578Phase 2Completed
NCT02736955Phase 3Completed

Competing Products

12 competing products in Tourette Syndrome

See all competitors
ProductCompanyStageHype Score
AZD5213 and placeboAstraZenecaPhase 2
52
PF-03654746 + Placebo + Placebo + PF-03654746PfizerPhase 2
51
AripiprazoleBristol Myers SquibbPre-clinical
22
NBI-98854Neurocrine BiosciencesPhase 2
49
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
49
ValbenazineNeurocrine BiosciencesPhase 2
49
NBI-98854Neurocrine BiosciencesPhase 1
30
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
49
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
Abobotulinum toxin AIpsenPre-clinical
20
Tetrabenazine MR + PlaceboBausch HealthPhase 2
47